In Vitro transformation of primary human CD34+ cells by aml fusion oncogenes: Early gene expression profiling reveals possible drug target in AML

PLoS ONE

Volumn 5, Issue 8, 2010, Pages

  Abdul Nabi, Anmaar M ^a   Yassin, Enas R ^a   Varghese, Nobish ^a   Deshmukh, Hrishikesh ^a   Yaseen, Nabeel R ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD34 ANTIGEN; NUTLIN 3; PROTEIN MDM2; PROTEIN P53;

ARTICLE; BONE MARROW CELL; CELL DIFFERENTIATION; CELL HYPERPLASIA; CELL MATURATION; CELL PROLIFERATION; CELL RENEWAL; CELL TRANSFORMATION; CONTROLLED STUDY; DRUG TARGETING; ERYTHROID CELL; FUSION GENE; GENE CONTROL; GENE EXPRESSION PROFILING; GENE NUMBER; HUMAN; HUMAN CELL; IN VITRO STUDY; NONHUMAN; ONCOGENE; ONCOGENE AML; ONCOGENE AML1 ETO; ONCOGENE MLL AF9; ONCOGENE NUP98 HOXA9; ONCOGENE PML RARA; UPREGULATION; ACUTE GRANULOCYTIC LEUKEMIA; CELL LINE; GENE EXPRESSION REGULATION; GENE FUSION; GENETICS; METABOLISM; PATHOLOGY; TIME;

ANTIGENS, CD34; CELL DIFFERENTIATION; CELL LINE; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LEUKEMIA, MYELOID, ACUTE; ONCOGENE FUSION; ONCOGENES; PROTO-ONCOGENE PROTEINS C-MDM2; TIME FACTORS;

EID: 77957891990     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0012464     Document Type: Article

References (60)

1. Grimwade D, Walker H, Oliver F, Wheatley K, Harrison C, et al. (1998) The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties. Blood 92: 2322-2333.
2. Look AT (1997) Oncogenic transcription factors in the human acute leukemias. Science 278: 1059-1064.
3. Vitoux D, Nasr R, de The H (2007) Acute promyelocytic leukemia: new issues on pathogenesis and treatment response. Int J Biochem Cell Biol 39: 1063-1070.
4. Meyer C, Kowarz E, Hofmann J, Renneville A, Zuna J, et al. (2009) New insights to the MLL recombinome of acute leukemias. Leukemia.
5. Schoch C, Schnittger S, Klaus M, Kern W, Hiddemann W, et al. (2003) AML with 11q23/MLL abnormalities as defined by the WHO classification: incidence, partner chromosomes, FAB subtype, age distribution, and prognostic impact in an unselected series of 1897 cytogenetically analyzed AML cases. Blood 102: 2395-2402.
6. Shih LY, Liang DC, Fu JF, Wu JH, Wang PN, et al. (2006) Characterization of fusion partner genes in 114 patients with de novo acute myeloid leukemia and MLL rearrangement. Leukemia 20: 218-223.
7. Chi Y, Lindgren V, Quigley S, Gaitonde S (2008) Acute myelogenous leukemia with t(6;9)(p23;q34) and marrow basophilia: an overview. Arch Pathol Lab Med 132: 1835-1837.
8. Graux C, Cools J, Melotte C, Quentmeier H, Ferrando A, et al. (2004) Fusion of NUP214 to ABL1 on amplified episomes in T-cell acute lymphoblastic leukemia. Nat Genet 36: 1084-1089.
9. Romana SP, Radford-Weiss I, Ben Abdelali R, Schluth C, Petit A, et al. (2006) NUP98 rearrangements in hematopoietic malignancies: a study of the Groupe Francophone de Cytogenetique Hematologique. Leukemia 20: 696-706.
10. Van Vlierberghe P, van Grotel M, Tchinda J, Lee C, Beverloo HB, et al. (2008) The recurrent SET-NUP214 fusion as a new HOXA activation mechanism in pediatric T-cell acute lymphoblastic leukemia. Blood 111: 4668-4680.
11. Rowley JD, Olney HJ (2002) International workshop on the relationship of prior therapy to balanced chromosome aberrations in therapy-related myelodysplastic syndromes and acute leukemia: overview report. Genes Chromosomes Cancer 33: 331-345.
12. Chou WC, Chen CY, Hou HA, Lin LI, Tang JL, et al. (2009) Acute myeloid leukemia bearing t(7;11)(p15;p15) is a distinct cytogenetic entity with poor outcome and a distinct mutation profile: comparative analysis of 493 adult patients. Leukemia.
13. Lam DH, Aplan PD (2001) NUP98 gene fusions in hematologic malignancies. Leukemia 15: 1689-1695.
14. McCormack E, Bruserud O, Gjertsen BT (2008) Review: genetic models of acute myeloid leukaemia. Oncogene 27: 3765-3779.
15. Grignani F, Valtieri M, Gabbianelli M, Gelmetti V, Botta R, et al. (2000) PML/RAR alpha fusion protein expression in normal human hematopoietic progenitors dictates myeloid commitment and the promyelocytic phenotype. Blood 96: 1531-1537.
16. Mulloy JC, Cammenga J, MacKenzie KL, Berguido FJ, Moore MA, et al. (2002) The AML1-ETO fusion protein promotes the expansion of human hematopoietic stem cells. Blood 99: 15-23.
17. Wunderlich M, Krejci O, Wei J, Mulloy JC (2006) Human CD34+ cells expressing the inv(16) fusion protein exhibit a myelomonocytic phenotype with greatly enhanced proliferative ability. Blood 108: 1690-1697.
18. Choi Y, Elagib KE, Delehanty LL, Goldfarb AN (2006) Erythroid inhibition by the leukemic fusion AML1-ETO is associated with impaired acetylation of the major erythroid transcription factor GATA-1. Cancer Res 66: 2990-2996.
19. Chung KY, Morrone G, Schuringa JJ, Plasilova M, Shieh JH, et al. (2006) Enforced expression of NUP98-HOXA9 in human CD34(+) cells enhances stem cell proliferation. Cancer Res 66: 11781-11791.
20. Takeda A, Goolsby C, Yaseen NR (2006) NUP98-HOXA9 induces long-term proliferation and blocks differentiation of primary human CD34+ hematopoietic cells. Cancer Res 66: 6628-6637.
21. Wei J, Wunderlich M, Fox C, Alvarez S, Cigudosa JC, et al. (2008) Microenvironment determines lineage fate in a human model of MLL-AF9 leukemia. Cancer Cell 13: 483-495.
22. Barabe F, Kennedy JA, Hope KJ, Dick JE (2007) Modeling the initiation and progression of human acute leukemia in mice. Science 316: 600-604.
23. Krejci O, Wunderlich M, Geiger H, Chou FS, Schleimer D, et al. (2008) p53 signaling in response to increased DNA damage sensitizes AML1-ETO cells to stress-induced death. Blood 111: 2190-2199.
24. Mulloy JC, Jankovic V, Wunderlich M, Delwel R, Cammenga J, et al. (2005) AML1-ETO fusion protein up-regulates TRKA mRNA expression in human CD34+ cells, allowing nerve growth factor-induced expansion. Proc Natl Acad Sci U S A 102: 4016-4021.
25. Wunderlich M, Mulloy JC (2009) Model systems for examining effects of leukemia-associated oncogenes in primary human CD34+ cells via retroviral transduction. Methods Mol Biol 538: 263-285.
26. Sutherland HJ, Lansdorp PM, Henkelman DH, Eaves AC, Eaves CJ (1990) Functional characterization of individual human hematopoietic stem cells cultured at limiting dilution on supportive marrow stromal layers. Proc Natl Acad Sci U S A 87: 3584-3588.
27. Elagib KE, Goldfarb AN (2007) Oncogenic pathways of AML1-ETO in acute myeloid leukemia: multifaceted manipulation of marrow maturation. Cancer Lett 251: 179-186.
28. Tusher VG, Tibshirani R, Chu G (2001) Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci U S A 98: 5116-5121.
29. Moll UM, Petrenko O (2003) The MDM2-p53 interaction. Mol Cancer Res 1: 1001-1008.
30. Vassilev LT, Vu BT, Graves B, Carvajal D, Podlaski F, et al. (2004) In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 303: 844-848.
31. Shangary S, Wang S (2009) Small-molecule inhibitors of the MDM2-p53 protein-protein interaction to reactivate p53 function: a novel approach for cancer therapy. Annu Rev Pharmacol Toxicol 49: 223-241.
32. Tonks A, Tonks AJ, Pearn L, Pearce L, Hoy T, et al. (2004) Expression of AML1-ETO in human myelomonocytic cells selectively inhibits granulocytic differentiation and promotes their self-renewal. Leukemia 18: 1238-1245.
33. Brunning RD, Porwit A, Orazi A, Baumann I, Germing U, et al. (2008) Myelodysplastic Syndromes. In: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, et al., editors. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th ed. Lyon: International Agency for Research on Cancer. pp. 87-107.
34. Drabkin HA, Parsy C, Ferguson K, Guilhot F, Lacotte L, et al. (2002) Quantitative HOX expression in chromosomally defined subsets of acute myelogenous leukemia. Leukemia 16: 186-195.
35. Golub TR, Slonim DK, Tamayo P, Huard C, Gaasenbeek M, et al. (1999) Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science 286: 531-537.
36. Eklund EA (2007) The role of HOX genes in malignant myeloid disease. Curr Opin Hematol 14: 85-89.
37. Westervelt P, Lane AA, Pollock JL, Oldfather K, Holt MS, et al. (2003) High-penetrance mouse model of acute promyelocytic leukemia with very low levels of PML-RARalpha expression. Blood 102: 1857-1865.
38. Bullinger L, Dohner K, Bair E, Frohling S, Schlenk RF, et al. (2004) Use of gene-expression profiling to identify prognostic subclasses in adult acute myeloid leukemia. N Engl J Med 350: 1605-1616.
39. Haferlach T, Kohlmann A, Schnittger S, Dugas M, Hiddemann W, et al. (2005) Global approach to the diagnosis of leukemia using gene expression profiling. Blood 106: 1189-1198.
40. Valk PJ, Verhaak RG, Beijen MA, Erpelinck CA, Barjesteh van Waalwijk, van Doorn-Khosrovani S, et al. (2004) Prognostically useful gene-expression profiles in acute myeloid leukemia. N Engl J Med 350: 1617-1628.
41. Wilson CS, Davidson GS, Martin SB, Andries E, Potter J, et al. (2006) Gene expression profiling of adult acute myeloid leukemia identifies novel biologic clusters for risk classification and outcome prediction. Blood 108: 685-696.
42. Lee S, Chen J, Zhou G, Shi RZ, Bouffard GG, et al. (2006) Gene expression profiles in acute myeloid leukemia with common translocations using SAGE. Proc Natl Acad Sci U S A 103: 1030-1035.
43. Schoch C, Kohlmann A, Schnittger S, Brors B, Dugas M, et al. (2002) Acute myeloid leukemias with reciprocal rearrangements can be distinguished by specific gene expression profiles. Proc Natl Acad Sci U S A 99: 10008-10013.
44. Debernardi S, Lillington DM, Chaplin T, Tomlinson S, Amess J, et al. (2003) Genome-wide analysis of acute myeloid leukemia with normal karyotype reveals a unique pattern of homeobox gene expression distinct from those with translocation-mediated fusion events. Genes Chromosomes Cancer 37: 149-158.
45. Wang JC, Dick JE (2005) Cancer stem cells: lessons from leukemia. Trends Cell Biol 15: 494-501.
46. Li Z, Luo RT, Mi S, Sun M, Chen P, et al. (2009) Consistent deregulation of gene expression between human and murine MLL rearrangement leukemias. Cancer Res 69: 1109-1116.
47. Slany RK (2009) The molecular biology of mixed lineage leukemia. Haematologica 94: 984-993.
48. Krug U, Ganser A, Koeffler HP (2002) Tumor suppressor genes in normal and malignant hematopoiesis. Oncogene 21: 3475-3495.
49. Banker DE, Radich J, Becker A, Kerkof K, Norwood T, et al. (1998) The t(8;21) translocation is not consistently associated with high Bcl-2 expression in de novo acute myeloid leukemias of adults. Clin Cancer Res 4: 3051-3062.
50. Pomerantz J, Schreiber-Agus N, Liegeois NJ, Silverman A, Alland L, et al. (1998) The Ink4a tumor suppressor gene product, p19Arf, interacts with MDM2 and neutralizes MDM2's inhibition of p53. Cell 92: 713-723.
51. Zhang Y, Xiong Y, Yarbrough WG (1998) ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways. Cell 92: 725-734.
52. Kruse JP, Gu W (2009) Modes of p53 regulation. Cell 137: 609-622.
53. Linggi B, Muller-Tidow C, van de Locht L, Hu M, Nip J, et al. (2002) The t(8;21) fusion protein, AML1 ETO, specifically represses the transcription of the p14(ARF) tumor suppressor in acute myeloid leukemia. Nat Med 8: 743-750.
54. Kojima K, Konopleva M, Samudio IJ, Shikami M, Cabreira-Hansen M, et al. (2005) MDM2 antagonists induce p53-dependent apoptosis in AML: implications for leukemia therapy. Blood 106: 3150-3159.
55. Long J, Parkin B, Ouillette P, Bixby D, Shedden K, et al. (2010) Multiple distinct molecular mechanisms influence sensitivity and resistance to MDM2 inhibitors in adult acute myelogenous leukemia. Blood 116: 71-80.
56. Isufi I, Seetharam M, Zhou L, Sohal D, Opalinska J, et al. (2007) Transforming growth factor-beta signaling in normal and malignant hematopoiesis. J Interferon Cytokine Res 27: 543-552.
57. Lin HK, Bergmann S, Pandolfi PP (2005) Deregulated TGF-beta signaling in leukemogenesis. Oncogene 24: 5693-5700.
58. Mikesch JH, Steffen B, Berdel WE, Serve H, Muller-Tidow C (2007) The emerging role of Wnt signaling in the pathogenesis of acute myeloid leukemia. Leukemia 21: 1638-1647.
59. Baum B, Settleman J, Quinlan MP (2008) Transitions between epithelial and mesenchymal states in development and disease. Semin Cell Dev Biol 19: 294-308.
60. Thiery JP, Sleeman JP (2006) Complex networks orchestrate epithelial-mesenchymal transitions. Nat Rev Mol Cell Biol 7: 131-142.